Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer is characterized by uncontrolled cell division due to genomic instability, which affects DNA damage response (DDR) networks.
• Conventional therapies damage healthy tissues, potentially promoting tumor resilience.
• Targeted DDR inhibition, like PARP inhibitors, shows success via synthetic lethality in specific cancer types.

Purpose of the Study:

• To review advances, challenges, and future directions in targeting the ATR-CHK1-WEE1 axis for cancer therapy.
• To explore the potential of CHK1 and WEE1 inhibitors in precision oncology.
• To highlight the need for understanding tumor-specific DDR defects and biomarkers.

Main Methods:

• Review of recent scientific literature on DNA damage response pathways and targeted cancer therapies.
• Analysis of the role of ATR-CHK1-WEE1 axis in replication stress and cell cycle checkpoints.
• Examination of clinical development and combination strategies for CHK1 and WEE1 inhibitors.

Main Results:

• The ATR-CHK1-WEE1 axis is a key regulator of replication stress and cell cycle checkpoints, offering a therapeutic window.
• CHK1 and WEE1 inhibitors demonstrate potential, particularly in combination with standard therapies, to induce selective tumor cell death.
• Successful targeting requires better understanding of tumor-specific DDR defects and robust biomarkers for patient stratification.

Conclusions:

• Targeting the ATR-CHK1-WEE1 axis represents a promising strategy for precision oncology.
• Combination therapies involving CHK1 and WEE1 inhibitors may enhance efficacy by exploiting elevated replication stress.
• Further research into DDR defects and biomarkers is crucial for clinical translation.